FindTrial
Sign In

clinical trial of Qingfei Paidu granule for treatment of COVID-19 in children

Efficacy and Safety of Qingfei Paidu granule for treatment of asymptomatic / mild / common COVID-19 infections in children

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200005962
Enrollment
Unknown
Registered
2022-05-03
Start date
2022-05-04
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

control group:Regular treatment
experimental group:Qingfei Paidu granule
experimental group:traditional Chinese medicine treatment recommended by Shanghai

Sponsors

Shanghai Children's Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
3 Years to 18 Years

Inclusion criteria

Inclusion criteria: 1) Aged 3 ~ 18 years old; 2) Coincidence the diagnostic criteria of the diagnosis and treatment plan for pneumonia infected by COVID-19 (trial version 9); 3) mild/ common/ asymptomatic COVID-19 infection; 4) The informed consent process complies with the regulations, and the legal guardian and/ or the test child (= 8 years old) jointly sign the ICF.

Exclusion criteria

Exclusion criteria: 1) Be are allergic to the test drug and intolerant to the drug; 2) cant ensure medication compliance during treatment and are difficult to give drugs by oral administration; 3) With basic respiratory diseases, malignant tumors, mental diseases and other malignant diseases of the system.

Design outcomes

Primary

MeasureTime frame
Negative time of COVID-19 nucleic acid test;—

Secondary

MeasureTime frame
hospital days;—

Countries

China

Contacts

Public ContactCao Qing
caoqing@scmc.com.cn+86 18930830511

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026